Title |
Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma
|
---|---|
Published in |
Hematology Journal, June 2018
|
DOI | 10.3324/haematol.2017.180505 |
Pubmed ID | |
Authors |
Clara Recasens-Zorzo, Teresa Cardesa-Salzmann, Paolo Petazzi, Laia Ros-Blanco, Anna Esteve-Arenys, Guillem Clot, Martina Guerrero-Hernández, Vanina Rodríguez, Davide Soldini, Alexandra Valera, Alexandra Moros, Fina Climent, Eva González-Barca, Santiago Mercadal, Leonor Arenillas, Xavier Calvo, José Luís Mate, Gonzalo Gutiérrez-García, Isolda Casanova, Ramón Mangues, Alejandra Sanjuan-Pla, Clara Bueno, Pablo Menéndez, Antonio Martínez, Dolors Colomer, Roger Estrada Tejedor, Jordi Teixidó, Elias Campo, Armando López-Guillermo, José Ignacio Borrell, Luis Colomo, Patricia Pérez-Galán, Gaël Roué |
Abstract |
Constitutive activation of the chemokine receptor CXCR4 has been associated with tumor progression, invasion, and chemotherapy resistance in different cancer subtypes. Although the CXCR4 pathway has recently been suggested as an adverse prognostic marker in diffuse large B-cell lymphoma, its biological relevance in this disease remains underexplored. In a homogeneous cohort of 52 patient biopsies, an antibody-based cytokine array showed that tissue levels of CXCL12 correlated with high microvessel density and bone marrow involvement at diagnosis, supporting a role for CXCL12-CXCR4 axis in disease progression. We then identified the tetra-amine IQS-01.01RS as a potent inverse agonist of the receptor, preventing CXCL12-mediated chemotaxis and triggering apoptosis in a panel of 18 cell lines and primary cultures, with superior mobilizing properties in vivo than standard agent. IQS-01.01RS activity was associated with downregulation of p-AKT, p-ERK1/2 and destabilization of MYC, allowing to a synergistic interaction with the bromodomain and extra-terminal domain inhibitor, CPI203. In a xenotransplant model of diffuse large B-cell lymphoma, IQS-01.01RS/CPI203 combination decreased tumor burden through MYC and p-AKT downregulation, and enhanced apoptosis induction. Thus, our results point out an emerging role of CXCL12-CXCR4 in the pathogenesis of diffuse large B-cell lymphoma and support the simultaneous targeting of CXCR4 and bromodomain proteins as a promising, rationale-based strategy for this disease. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 4 | 80% |
Unknown | 1 | 20% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 2 | 40% |
Members of the public | 2 | 40% |
Scientists | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 46 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 10 | 22% |
Student > Bachelor | 7 | 15% |
Student > Master | 5 | 11% |
Professor > Associate Professor | 4 | 9% |
Student > Ph. D. Student | 3 | 7% |
Other | 6 | 13% |
Unknown | 11 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 17 | 37% |
Chemistry | 5 | 11% |
Medicine and Dentistry | 5 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
Agricultural and Biological Sciences | 2 | 4% |
Other | 2 | 4% |
Unknown | 12 | 26% |